Secondary outcomes after dosing with pharmacogenetics-based algorithm
| Initiation phase (day 1-9), n (%) | |
| INR 2-3 within 3 days | 13 (7.8) |
| INR 2-3 within 6 days | 67 (40.1) |
| INR 2-3 within 9 days | 96 (57.5) |
| INR extended 1.8-3.2 within 3 days | 23 (13.8) |
| INR extended 1.8-3.2 within 6 days | 101 (60.5) |
| INR extended 1.8-3.2 within 9 days | 131 (78.4) |
| INR ≥ 5 | 0 (0) |
| 90-day follow-up period* | |
| Time spent in range, % (SD) | 64.8 (19.8) |
| Time spent in extended therapeutic INR range (1.8-3.2), % (SD) | 77.3 (14.4) |
| Time spent in INR ≥ 4, % (SD) | 1.2 (2.9) |
| Number of INR measurements in 90 days, mean ± SD | 12.3 ± 2.7 |
| INR ≥ 5, n (%) | 6 (3.6) |
| Post 30-day follow-up period | |
| Time spent in range, % (SD) | 68.1 (25.0) |
| Initiation phase (day 1-9), n (%) | |
| INR 2-3 within 3 days | 13 (7.8) |
| INR 2-3 within 6 days | 67 (40.1) |
| INR 2-3 within 9 days | 96 (57.5) |
| INR extended 1.8-3.2 within 3 days | 23 (13.8) |
| INR extended 1.8-3.2 within 6 days | 101 (60.5) |
| INR extended 1.8-3.2 within 9 days | 131 (78.4) |
| INR ≥ 5 | 0 (0) |
| 90-day follow-up period* | |
| Time spent in range, % (SD) | 64.8 (19.8) |
| Time spent in extended therapeutic INR range (1.8-3.2), % (SD) | 77.3 (14.4) |
| Time spent in INR ≥ 4, % (SD) | 1.2 (2.9) |
| Number of INR measurements in 90 days, mean ± SD | 12.3 ± 2.7 |
| INR ≥ 5, n (%) | 6 (3.6) |
| Post 30-day follow-up period | |
| Time spent in range, % (SD) | 68.1 (25.0) |
Ninety-day follow-up period excludes initiation phase (days 1-9). The outcomes change slightly when initiation is included.